Event

Connect with Quotient Sciences at the upcoming BIO International Convention 2023 in Boston, MA between June 5-8.

Schedule a meeting

Resources

Resource centre

Peer Reviewed Publication

Astrazeneca - A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism and Excretion of Savolitinib in Healthy Male Volunteers

Quotient Sciences and Astrazeneca Co-Authored Scientific Publication evaluating Savolitinib in healthy male volunteers.

Strategies for Achieving Regulatory Milestones Faster

Watch our on-demand webinar featuring a customer case study from Ensysce Biosciences' CEO Lynn Kirkpatrick on choosing an integrated service provider to accelerate drug development.

Quotient Sciences and Charles River Collaboration Webinar

Watch Quotient Sciences & Charles River webinar on-demand entitled, 'Integrated Strategies for Accelerating from Discovery to IND and Beyond: Charles River & Quotient Sciences Collaboration'.

Bioanalytical Strategies for Insulin Analogues & Other Large Peptides Using LC-MS

Learn how our physiochemical-based approach enables us to accelerate the development of bioanalytical assays for insulin analogues from Michael Blackburn, Head of Bioanalytical Method Development and Labs.

The First Kilograms of GMP Drug Substance

A core component of Quotient Sciences is our integrated capabilities in drug substance process research, development, and manufacturing. All are carried out at our state-of-the-art facility in Alnwick, UK.

Conference Report from the European Bioanalysis Forum Workshop: toward harmonized implementation of the ICH M10 guideline

In this report, the European Bioanalysis Forum shares the proposals for harmonized implementation of the ICH M10 guideline on bioanalytical method validation and study sample analysis from the ICH M10 workshop.

Peer Reviewed Publication

Astrazeneca - Mass balance recovery and disposition of AZD4831 in humans

Quotient Sciences and Astrazeneca Co-Authored Scientific Publication evaluating the mass balance recovery and disposition of AZD4831 in humans.

Synthesis to Clinic: A streamlined approach to 14C human ADME studies

We are a leading provider of 14C-enabled drug development programs, successfully conducting over 350 human ADME and other radiolabeled programs to date. Learn about Synthesis-to-Clinic®.

Scientific Posters

The use of electrospraying as a means of drug loading into mesoporous silica particles for enhanced dissolution

The use of electrospraying as a means of drug loading into mesoporous silica particles for enhanced dissolution, presented at the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology 2022

Navigating the Small Molecule CMC Pathway

Learn about drug substance and formulation considerations for improving downstream clinical outcomes. Access on demand.

Scientific Posters

Safety, tolerability, and pharmacokinetics of the oligomer modulator anle138b: a first-in-human randomised, double-blind, placebo-controlled Phase 1 trial

Safety, tolerability, and pharmacokinetics of the oligomer modulator anle138b: a first-in-human randomised, double-blind, placebo-controlled Phase 1 trial

Peer Reviewed Publication

Practical and operational considerations related to paediatric oral drug formulation: An industry survey

Practical and operational considerations related to paediatric oral drug formulation: An industry survey.